Hypoactive Sexual Desire Disorder in Males

Description

The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).

Conditions

Low Libido

Study Overview

Study Details

Study overview

The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).

Hypoactive Sexual Desire Disorder in Males (10-18-40-13)

Hypoactive Sexual Desire Disorder in Males

Condition
Low Libido
Intervention / Treatment

-

Contacts and Locations

Houston

Baylor College of Medicine, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men age 18 through 69 years old
  • * Men who are distressed by their low libido as defined by SDI-2, and SCI-M questionnaires. (Appendices A,C)
  • * Men who are not depressed as defined by PHQ-9 (Patient Health Questionnaire) score of 9 or less. (Appendix D)
  • * Men with good erectile function as defined by IIEF greater than 22
  • * Men with normal testosterone and liver function values (may be on testosterone therapy)
  • * Men who are satisfied in their relationship or with their partners
  • * Men or their female partners must be willing to use one form of contraception throughout the study and 30 days after final study visit.
  • * Willing to give informed consent
  • * Hypogonadal patients (less than 350 ng/dL)
  • * IIEF-EF less than 22
  • * CYP3A4 and CYP2C19 inhibitors Use of moderate or strong CYP3A4 inhibitors is prohibited for the duration of the trial, and if such medication becomes necessary, flibanserin treatment must be suspended until 2 weeks after the last dose of the CYP3A4 inhibitor
  • * Hepatic impairment not greater than 1.5 upper limit of normal of AST/ALT
  • * Men with normal to high libido
  • * Depressed patients as assessed by the PHQ-9 questionnaire as defined as 10 or greater.
  • * Men who are stressed or fatigued as determined by the PI
  • * Men with partners who have low libido as determined by the PI
  • * Men with pre-existing conditions that might predispose to hypertension
  • * Men who are not willing to meet the requirements for drinking alcohol during their participation in the study
  • * Men who are taking digoxin

Ages Eligible for Study

18 Years to 69 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mohit Khera,

Mohit Khera, MD, MBA, MPH, PRINCIPAL_INVESTIGATOR, Baylor College of Medicine

Study Record Dates

2026-12-31